Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recent Breakthrough Designations Break New Ground

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Vaccines and gene therapies are added to the list of types of drugs that could garner the expedited development pathway from the U.S. regulatory agency, with Novartis and Celladon being the most recent companies to tout the status.

You may also be interested in...



Pressure For Bexsero: Fate Of Novartis Vaccines Unit Hangs On Success

The EU CHMP’s recommendation in favor of Novartis’ Meningitis B vaccine Bexsero is a positive turn for the company’s vaccines business, but with the division’s sales and profits languishing, some investors are wondering if Novartis should cut its losses and get out of the space.

Celladon Hopes To Bring Gene-Therapy Solution To Heart Failure Patients

Improving heart contractility by increasing levels of the SERCA2a gene is a new approach to a familiar problem in treating heart failure.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS005713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel